List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chemotherapy Induced Anemia - Overview
Chemotherapy Induced Anemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Chemotherapy Induced Anemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development
Cadila Healthcare Ltd
FibroGen Inc
Jecho Biopharmaceuticals Co Ltd
Panacea Biotec Ltd
PharmaEssentia Corp
PhytoHealth Corp
SBI Pharmaceuticals Co Ltd
Sumitomo Dainippon Pharma Oncology, Inc
Therapure Biopharma Inc
UBI Pharma Inc
Vifor Pharma Ltd
Chemotherapy Induced Anemia - Drug Profiles
(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
darbepoetin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
desidustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erythropoietin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ferric carboxymaltose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JL-14001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-1116 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PHEP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
roxadustat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBI-304H - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-0184 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chemotherapy Induced Anemia - Dormant Projects
Chemotherapy Induced Anemia - Discontinued Products
Chemotherapy Induced Anemia - Product Development Milestones
Featured News & Press Releases
Jul 23, 2020: Zydus receives approval from USFDA to initiate clinical trials of Desidustat in cancer patients receiving chemotherapy
Sep 26, 2019: FibroGen announces initiation of phase 2 clinical trial of Roxadustat for the treatment of anemia in cancer patients receiving chemotherapy
Feb 27, 2019: Tolero Pharmaceuticals to present new data evaluating investigational agent TP-0184 at AACR Annual Meeting 2019
Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H
Oct 30, 2012: SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia
Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health
Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology
Oct 21, 2011: ALA Study Results Presented at 39th Annual Meeting of Japanese Association for Acute Medicine
Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting
Oct 03, 2011: ALA Study Results Presented at Japanese Society of Parasitology, 71st Meeting
Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Chemotherapy Induced Anemia, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Chemotherapy Induced Anemia - Pipeline by Cadila Healthcare Ltd, H2 2020
Chemotherapy Induced Anemia - Pipeline by FibroGen Inc, H2 2020
Chemotherapy Induced Anemia - Pipeline by Jecho Biopharmaceuticals Co Ltd, H2 2020
Chemotherapy Induced Anemia - Pipeline by Panacea Biotec Ltd, H2 2020
Chemotherapy Induced Anemia - Pipeline by PharmaEssentia Corp, H2 2020
Chemotherapy Induced Anemia - Pipeline by PhytoHealth Corp, H2 2020
Chemotherapy Induced Anemia - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2020
Chemotherapy Induced Anemia - Pipeline by Sumitomo Dainippon Pharma Oncology, Inc, H2 2020
Chemotherapy Induced Anemia - Pipeline by Therapure Biopharma Inc, H2 2020
Chemotherapy Induced Anemia - Pipeline by UBI Pharma Inc, H2 2020
Chemotherapy Induced Anemia - Pipeline by Vifor Pharma Ltd, H2 2020
Chemotherapy Induced Anemia - Dormant Projects, H2 2020
Chemotherapy Induced Anemia - Dormant Projects, H2 2020 (Contd..1), H2 2020
Chemotherapy Induced Anemia - Discontinued Products, H2 2020

List of Figures
Number of Products under Development for Chemotherapy Induced Anemia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

Companies Mentioned
• Cadila Healthcare Ltd
• FibroGen Inc
• Jecho Biopharmaceuticals Co Ltd
• Panacea Biotec Ltd
• PharmaEssentia Corp
• PhytoHealth Corp
• SBI Pharmaceuticals Co Ltd
• Sumitomo Dainippon Pharma Oncology, Inc
• Therapure Biopharma Inc
• UBI Pharma Inc
• Vifor Pharma Ltd